Abstract-Refractory
R efractory hypertension (RfHTN), an extreme phenotype of antihypertensive failure, is defined as failure to control blood pressure (BP) with ≥5 antihypertensive agents, including chlorthalidone and a MR (mineralocorticoid receptor) antagonist. 1 This phenotype represents a subgroup of patients with resistant hypertension (RHTN) defined as lack of BP control in spite of the use of ≥3 antihypertensive agents, including a diuretic, or controlled BP with use of ≥4 antihypertensive agents, so-called controlled RHTN. 2 The prevalence of RfHTN among patients referred to hypertension specialty clinics has been reported to be between 5% and 10%. 3, 4 RfHTN patients are more often women and of African ancestry as compared with patients with controlled RHTN. 1 Furthermore, patients with RfHTN have persistent BP elevation by ambulatory monitoring and a low rate of white coat effect. 5 Not surprisingly, large, community-based cohort studies have shown that RfHTN is associated with an increased risk of stroke and coronary heart disease as compared with hypertensive patients in general. 4 Prior studies have indicated that RHTN is generally attributable to persistent intravascular fluid retention. Taler et al 6 found that thoracic fluid content was increased in patients with uncontrolled RHTN, and intensification of diuretic therapy was necessary to counteract this fluid retention to control BP. In a study by Gaddam et al, 7 patients with uncontrolled RHTN with higher levels of B-type natriuretic peptide (BNP) along with greater left atrial (LA) and left ventricular (LV) volumes had significant improvement in BP, and normalization of intracardiac volumes after diuresis was enhanced using spironolactone.
In contrast, few recent studies have demonstrated that thoracic fluid content is similar in patients with RfHTN and controlled RHTN. 1 However, the RfHTN patients had elevated heart rate and urinary normetanephrine levels as compared with controlled RHTN. 1, 8 These differences suggest a potential mechanistic distinction between RfHTN and RHTN in general in that RfHTN may be more neurogenic in cause, that is, secondary to excess sympathetic output, as opposed to being volume dependent, that is, persistent intravascular fluid retention, as is typical of RHTN. If true, such a mechanistic distinction would have important therapeutic implications in that the treatment of RfHTN may require more effective sympatholytic therapies for BP control as opposed to further intensification of diuretic therapy.
The objective of our study was to determine whether antihypertensive treatment failure in patients with RfHTN is characterized by persistent intravascular fluid retention as demonstrated by higher LA and LV end-diastolic (LVED) volumes and higher BNP levels. Patients with controlled RHTN served as the comparator group. We performed extensive laboratory testing and cardiac phenotyping of patients with RfHTN to assess ventricular dimensions, ventricular function, and the LV mass/volume ratio as compared with controlled RHTN.
Methods
The authors declare that all supporting data are available within the article.
Study Population
We prospectively enrolled consecutive patients who were referred to the University of Alabama at Birmingham Hypertension Clinic for uncontrolled RHTN (automated office BP [AOBP] >135/85 mm Hg with use of ≥3 antihypertensive medications, including a diuretic) between April 2014 and January 2018. RfHTN was defined as lack of BP control despite the use of ≥5 antihypertensive agents, including chlorthalidone and an MR antagonist, typically spironolactone, after a minimum of 3 follow-up visits. Office BP readings were obtained using AOBP as described below. All patients were evaluated for hyperaldosteronism and pheochromocytoma. Renal artery stenosis was assessed if clinically indicated. Exclusion criteria were nonadherence based on self-report or low medication refill rates; chronic kidney disease stages 4 or 5 (estimated glomerular filtration rate <30 mL/min per 1.73 m 2 ), or if pregnant or nursing. All patients underwent 24-hour ambulatory BP monitoring (ABPM). RfHTN patients with white coat effect (defined as ambulatory awake BP <135/85 mm Hg and clinic AOBP >135/85 mm Hg) were excluded, as well as controlled RHTN with uncontrolled masked hypertension, (defined as ambulatory awake BP >135/85 mm Hg and clinic AOBP <135/85 mm Hg). The University of Alabama at Birmingham Institutional Review Board approved the study, and written informed consent was obtained from all participants.
Automated Office BP Measurement
The clinic AOBP was measured using the BpTRU device (Coquitlam BC, Canada), after at least 5 minutes of quiet rest in a sitting position with the back supported and the arm supported at heart level. 9 An appropriate sized cuff was used with a cuff bladder encircling at least 80% of the arm. 10, 11 The BpTRU AOBP device automatically obtains 6 serial BP readings, 1 minute apart, before displaying the average of the last 5 readings with mean arterial pressure and BP variability. The assessments were unattended, that is, unobserved in clinic. 10, [12] [13] [14] [15] A BP cutoff of ≥135/85 mm Hg for elevated BP was used based on recent literature validating automated BP devices. 16, 17 Twenty-Four Hours ABPM Study patients also underwent ABPM using an automated, noninvasive, oscillometric device (Oscar 2; SunTech Medical Inc, Morrisville, NC). 18, 19 ABPM measurements were obtained every 20 minutes during the daytime (awake) and every 30 minutes during the night-time (asleep) phases of the 24-hour period. Awake and asleep times were self-reported by the patient. ABPM was determined to be valid if >80% of measurements were successful. Controlled BP by ABPM was defined as mean daytime (awake) BP <135/85 mm Hg. 18, 19 
Cardiac Magnetic Resonance Imaging
All patients underwent cardiac magnetic resonance (CMR) to evaluate cardiac and aortic structure and function. CMR was performed with a 1.5-T clinical scanner optimized for cardiac imaging (Signa, GE Healthcare) using a 4-element phased-array surface coil and prospective electrocardiographic triggering as described previously. 20 Imaging was performed using a rapid steady-state free precession cine sequence (10 k-space lines per segment). Standard short-axis and 2-and 4-chamber images were obtained from appropriate scout images and used for all the quantitative of right ventricular, LV, and LA volumes. Cine images were reconstructed into 20 cardiac phases. Slice thickness for the short-axis, 2-chamber, and 4-chamber images was 8 mm without any slice gap. The following parameters were used: matrix size, 256×128; field of view, 40×40 cm; typical repetition time, 3.9 ms; typical echo time, 1.6 ms; flip angle, 45°; bandwidth, 125 Hz per pixel; and typical acquired temporal resolution, 39 ms. CAAS Flow and CAAS MRV software (Pie Medical Imaging, Maastricht, the Netherlands) was used to evaluate ventricular and atrial volume and function. LA contours were manually drawn on 2-and 4-chamber long-axis views at ventricular end systole; this phase corresponds with the largest LA area. The inferior LA border was defined as the plane of the mitral annulus. We excluded the pulmonary veins and the LA appendage as recommended by echocardiographic guidelines. 21 The LA base-to-mitral-valve length was obtained from the middle of the plane of the mitral annulus to the posterior wall. LA volume was calculated by the arealength method V=8/3π (A 2ch A 4ch /L), where A 2ch and A 4ch represent the LA area acquired from the long-axis 2-and 4-chamber views by planimeter, respectively, and L is the shortest length from basal wall to the mitral valve annulus. Short-axis cine MR imaging (MRI) was performed, and the epicardial and endocardial contours of the ventricles at end systole and end diastole were manually drawn for each slice. 22 Chamber volumes and LV mass were indexed to the body surface area. Ventricular ejection fraction (EF) was calculated as EF=(EDV−ESV)/EDV×100, where EDV stands for end-diastolic volume and ESV for end-systolic volume.
For assessment of diastolic function, segmentation for each shortaxis slice was performed across all temporal phases. Volumetric data were used to analyze the LV volume-filling time course. 23, 24 The following CMR diastolic parameters were evaluated:
1. Peak filling rate: Maximal LV filling rate defined by maximal change in LV volume between sequential temporal phases (Δ volume/Δ phase). This index was also adjusted for stroke volume to generate normalized peak filling rate. 24 2. Diastolic volume recovery: Proportion of diastole required for recovery of 80% of stroke volume. 24 The LV inflow contour was manually traced throughout the cardiac cycle, and velocity encoded, phase contrast MRI was performed to obtain early and late LV filling velocities. 25 
Statistical Analysis
Descriptive statistics are presented as mean±SD, median with range, or frequency number and percentage within the group, as appropriate. Between-group differences were compared by independent Student t test or nonparametric Wilcoxon rank-sum test for continuous variables, as appropriate, and by χ 2 test for categorical variables. The P values are provided for descriptive purposes.
Reported P values are 2 sided with P<0.002 considered significant after applying a Bonferroni correction for multiple testing of cardiac parameters. Differences in baseline characteristics (Tables 1  and 2 ) are considered statistically significant for P<0.05. Data analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC).
Results
A total of 224 patients were screened for study participation. After diagnostic testing, 24 patients with RfHTN were enrolled and 30 patients with controlled RHTN were recruited for the A modest linear association within the 2 groups was found between systolic BP and LV mass (Pearson correlation, 0.308; P=0.023), along with diastolic BP and LV mass (Pearson correlation, 0.502; P<0.001; Figure S1A and S1B in the onlineonly Data Supplement).
CMR-Derived Measurements

Cardiac Morphology
Systolic and Diastolic Functions
Volumetric assessment by MRI did not reveal differences in right ventricular or LV EF among groups. Furthermore, flow assessment across ascending aorta did not reveal differences in cardiac output or stroke volume (Table 4) . Although most of the diastolic function parameters were not different between groups, the RfHTN group showed impaired diastolic function evidenced by a lower peak filling rate (normalized by LV stroke volume) compared with the RHTN group (Table 3) . RfHTN patients had higher resting heart rates, which was reflected by a trend toward a shorter time in diastole (497.3±95.9 versus 564.7±128.7 ms; P=0.04).
Discussion
There are several key findings of our study. This is the first detailed cardiovascular phenotyping of patients with RfHTN using CMR, a technique considered to be the gold standard for the assessment of cardiac structure and function. Second, we found no difference in LA and LVED volume between the 2 study groups along with similar levels of BNP, suggesting that patients with RfHTN do not have persistent fluid retention as a cause of their antihypertensive treatment failure. Third, our study demonstrated more pronounced cardiac remodeling in RfHTN subjects as evidenced by increased LV mass and wall thickness, without significant increases in chamber volume as compared with patients with controlled RHTN. Fourth, systolic function was preserved in both groups. However, there was evidence for abnormal diastolic filling in patients with RfHTN as compared with controlled RHTN subjects. Persistent fluid retention is thought to broadly underlie the development of RHTN. Taler et al 6 reported that RHTN is characterized by intravascular fluid retention, as evidenced by increased thoracic impedance and the observation that intensification of diuretic therapy facilitated better BP control in these patients. Our group previously reported that patients with RHTN have greater end-diastolic volumes and higher BNP levels than control patients without RHTN 7, 26 and that this fluid retention could be overcome with use of spironolactone. 7 In the current study, we did not observe any significant differences in cardiac chamber volumes or BNP levels between patients with RfHTN and patients with controlled RHTN, arguing against persistent fluid retention as the cause of the antihypertensive treatment failure. This suggests that alternative mechanisms may be driving the lack of treatment response. The higher resting heart rates and higher urinary metanephrine levels observed in earlier studies suggest heightened sympathetic activity as a potential cause of RfHTN. If so, this carries important clinical implications in that such patients failing maximal or near-maximal antihypertensive treatment may best respond to more effective sympatholytic interventions, either pharmacologic or device-based, as opposed to continued intensification of diuretic therapy, which has been generally recommended for continued lack of BP control in patients with RHTN.
The current study demonstrates that patients with RfHTN have a greater prevalence of LV hypertrophy, characterized by a greater LV mass index and wall thickness as compared with patients with controlled RHTN. Previous studies of patients with RfHTN have likewise reported a high prevalence of LV hypertrophy based on ECG criteria 4 and M-mode echocardiography. 8 The greater LV mass is no doubt attributable, at least in part, to the longstanding, poorly controlled hypertension characteristic of RfHTN.
There were no differences in systolic function between the 2 study groups. However, patients with RfHTN had signs of diastolic dysfunction or subclinical heart failure with preserved EF. First, the LV mass/LVED volume ratio in the RfHTN group was >1 g/mL and greater than in the control group, concordant with findings from prior studies in patients with heart failure with preserved EF. 27 Second, RfHTN subjects showed a delayed LV filling pattern that has been described in patients with diastolic dysfunction, 24 as well as in clinical heart failure, despite no differences in EF among groups. Although we did not detect differences between the 2 study groups, the small sample size of patients with RfHTN reduces the statistical power of the analysis, increasing risk of a type II error. Study limitations include the small number of patients with RfHTN. Study strengths include the rigorous characterization of the 2 phenotypes based on extensive biochemical testing, ABPM, and cardiac MRI.
In conclusion, the current study demonstrates similar intracardiac chamber volumes and BNP levels in patients with RfHTN and controlled RHTN, suggesting that antihypertensive treatment failure in these patients is not from lack of effective diuresis when treated with chlorthalidone and spironolactone. Instead, it suggests a mechanism of treatment failure separate from persistent fluid retention, such as increased sympathetic tone. 1 Further, patients with RfHTN have evidence of adverse cardiovascular remodeling compared with controlled RHTN, placing them at increased risk for adverse cardiovascular events.
1,28
Perspectives
Patients with RfHTN represent a subset of individuals with hypertension that remains uncontrolled despite maximal antihypertensive treatment, including use of long-acting thiazide diuretics and MR antagonists. Our detailed cardiac phenotyping analysis using CMR demonstrated greater ventricular wall thickness without chamber enlargement in patients with RfHTN compared with patients with controlled RHTN. These findings are in agreement with prior studies from our group, suggesting that the failure of antihypertensive to control BP in RfHTN is not attributable to persistent fluid retention but instead is mediated by other mechanisms, such as increased sympathetic tone.
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